SCHEMBL5669798

SCHEMBL5669798

O=C(NO)C(Cc1ccccc1)CS(=O)(=O)N1CCC(c2ccccc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 3/20 0.44
MMP2 P08253 2/20 0.44
ADAM10 O14672 1/20 0.44
MMP9 P14780 1/20 0.44
CHRM4 P08173 1/20 0.42
CTSS P25774 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151590 0.88 MMP3 (0.40) MMP3MMP2ADAM10MMP9CHRM4
SCHEMBL5669557 0.88 ADAM10 (0.44) MMP3MMP2ADAM10CTSSHDAC3
SCHEMBL5670324 0.87 RBP4 (0.51) MMP2ADAM10CTSSHDAC3HDAC4
SCHEMBL5670555 0.85 MEN1 (0.48) MMP2MMP9CHRM4ALDH1A1MAPT
SCHEMBL5670514 0.81 ADAM10 (0.45) MMP3MMP2ADAM10MMP9CHRM4
SCHEMBL4611356 0.81 HSD17B10 (0.54) CTSSALDH1A1HSD17B10
SCHEMBL5671594 0.81 ADAM10 (0.45) MMP3MMP2ADAM10MMP9CHRM4
SCHEMBL4609998 0.76 GRM5 (0.47) CTSSALDH1A1HSD17B10
SCHEMBL5671567 0.76 OPRL1 (0.43) ADAM10ALDH1A1CYP2C19
SCHEMBL5671570 0.76 OPRL1 (0.43) ADAM10ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 MMP3 17/4885MMP2 264/4885ADAM10 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.